Thus, reducing insulin resistance by reduction of phospho-IRS-1ser307 levels and phospho-IRS-1ser307/IRS-1 in the liver may be a novel strategy for the treatment of NASH. Here, IRS1 is linked to metabolic dysfunction-associated steatohepatitis.